Results: In NCI-H441 cells, methylprednisolone treatment at 10 À5 M and 10 À6 M reduced surfactant protein A1 and surfactant protein A2 messenger RNA and surfactant protein A protein expression (P<.05). A pharmacogenetic relationship was observed in human donor precision-cut lung slices between the surfactant protein A2 (1A x ) variants: Surfactant protein A1, A2, and D messenger RNA expression were greater for 1A 0 versus 1A 1 (P <.05); surfactant protein A1/surfactant protein A2 genotype 6A 2 6A 2 /1A 0 1A 0 (n ¼ 5) showed greater surfactant protein A1, A2, and D messenger RNA expression and surfactant protein A protein expression compared with the other surfactant protein A1/surfactant protein A2 genotypes (n ¼ 11) (P <.05). 
Conclusions:

Central Message
Our study, although acquired from a small cohort of human donor lungs, for the first time showed that the SP-A genotype and methylprednisolone stimuli influence donor lung SP-A and SP-D expression.
Perspective
This study, as the first reference for future pharmacogenetic studies in lung transplantation, may provide the basis for novel immunosuppressive regimens tailored according to the genetic background of the donor lung. Further studies are required on donor lungs for the purposes of identifying different genotypes to predict the response of these genotypes to methylprednisolone treatment.
See Commentaries on pages 2118 and 2119.
To date, lung transplantation is a good option to counter end-stage lung disease. Long-term outcome is still challenged by multiple dangerous events (ie, infections, rejection, and gastroesophageal reflux micro-aspiration) that contribute to a suboptimal survival. [1] [2] [3] Pulmonary surfactant provides the lung with one of its innate defense mechanisms consisting of a mixture of phospholipids and surfactant protein (SP)-A, SP-D, SP-B, and SP-C. [4] [5] [6] SP-A and SP-D (collectins serving as opsonins) have also been shown to orchestrate lung immunity by regulating cytokine production in macrophages and neutrophils while also providing direct or indirect modulation of lymphocyte proliferation. 7, 8 Determining the regulation of these proteins in lung transplantation is important when selecting the optimal treatment strategy.
Human SP-A and SP-D genes reside in the same chromosome (10q22.2-23.1). SP-A is encoded by 2 genes, SP-A1 and SP-A2, with several polymorphisms within the coding region. 9, 10 Three coding single nucleotide polymorphisms (SNPs) of the SP-D gene have been described for amino acid residue 11 (Met 11 Thr), 160 (Ala 160 Thr), and 270 (Ser 270 Thr), the latter being infrequent. 11, 12 Gene polymorphisms of the SP-A1, SP-A2, and SP-D proteins may be responsible for quantitative or qualitative differences that may include reduced levels of protein production and variations in protein functionality.
9,10 SP-A and SP-D gene variants are associated with respiratory distress syndrome, idiopathic pulmonary fibrosis, emphysema, and other lung diseases. [11] [12] [13] [14] [15] [16] [17] [18] [19] Expression of SP-A and SP-D is regulated by cAMP, thyroid transcription factor-1, and glucocorticoids. [20] [21] [22] SP-A genes and variants have been suggested to display a variety of responses to glucocorticoids. [20] [21] [22] This is of interest in lung transplantation given that donor lungs are treated with elevated doses of methylprednisolone before organ retrieval and that the recipient standard immunosuppressive regimen also includes relatively high doses of prednisone. 23 Lung allografts with low levels of SP-A messenger RNA (mRNA) expression just before implantation are associated with reduced survival. 24 Furthermore, donor lung SP-A2 polymorphisms are associated with greater incidence of pneumonia and reduced survival. 25 In contrast, SP-D variants were associated with development of chronic lung allograft dysfunction. 26 Given these observations, we hypothesized a pharmacogenetic relationship of SP-A and SP-D variants and methylprednisolone. This would be relevant in the context of lung transplantation because lung allografts are exposed to high levels of steroids both before procurement and during the first post-transplant period. By using donor precision-cut lung slices (PCLS) and cell cultures in vitro, we studied the effect of methylprednisolone on SP-A and SP-D expression according to the different genotypes as determined by the SP-A1 and SP-A2 haplotypes and the 2 most frequent SP-D variants, residue 11 Reverse Transcription-Polymerase Chain Reaction RNA was isolated with RNeasy kits (QIAGEN, Valencia, Calif). RNA was reverse transcribed to cDNA using the High-Capacity cDNA Kit (Applied Biosystems, Carlsbad, Calif). Quantitative polymerase chain reaction was performed using the TaqMan Gene Expression Assays in an ABI 7300H polymerase chain reaction system (Applied Biosystems). TaqMan primers for SP-A1 (HS01921510_S1), SP-A2 (HS00359837_M1), SP-D (HS01108490_M1), glyceraldehyde-3-phosphate dehydrogenase (GADPH) (HS999999905M1), and 18S rRNA (Hs99999901_s1) were used. GADPH and 18S rRNA served as endogenes for cells and PCLS, respectively. Relative quantification was calculated.
Protein Quantification
Cells were homogenized in RIPA lysis buffer (Thermo Fisher, Rockford, Ill). The homogenate was centrifuged for 10 minutes at 13,000g. Proteins were quantified using the BioRad assay (BioRad, Hercules, Calif). Immunoblots were undertaken with 10 mg of human SP-A antibody (Santa Cruz Biotechnology, Santa Cruz, Calif) at 0.2 mg/mL. Blots were detected by anti-goat horseradish peroxidase-conjugated secondary antibody, followed by enhanced horseradish peroxidase chemiluminescence (Thermo Fisher) and autoradiography. Bands were semiquantified using Quantity One Image software (Kodak MI 4.0). Cell protein levels were normalized to GADPH or cyclophilin A (Abcam, Cambridge, Mass). Thr were assessed using a pyrosequencing protocol as previously described. 10, 19, 27 Pyrograms were scored by pattern-recognition software comparing the predicted single nucleotide polymorphism pattern (histogram) with the observed pattern (pyrogram) (Pyrosequencing AB, Uppsala, Sweden).
Surfactant Protein Genotype
Abbreviations and Acronyms
GAPDH ¼ glyceraldehyde-3-phosphate dehydrogenase mRNA ¼ messenger RNA PCLS ¼ precision-cut lung slices SP ¼ surfactant protein
Statistical Analysis
RNA and protein expression are reported as median (25th-75th percentile range). Box plot graphs represent the median at the 25th-75th percentile range and bars at the 10th and 90th percentile. We used Kruskal-Wallis tests to compare continuous variables across categories. When the Kruskal-Wallis test was P less than .05, we used the Mann-Whitney test to compare continuous variables between categories to preserve an overall alpha of 0.05. Statistical analysis was performed using SAS 9.2 software (SAS Institute Inc, Cary, NC).
RESULTS
Methylprednisolone Treatment of Human Lung Cells
The NCI-H441 cells were used because they express SP-A 28 Methylprednisolone treatment of the PCLS with high (10 À5 M) or low (10 À9 M) doses showed no difference in the SP-A1 and SP-A2 mRNA expression in all groups (Table 3) . Subsequent data comparisons between groups were performed irrespective of the methylprednisolone dose.
After methylprednisolone treatment, donor PCLS grouped for SP-A1 variants showed that SP-A1 mRNA expression was for variant 6A 2 median 2.9 (2.4-3.7) and for 6A 3 median 1 (0.3-3.9). SP-A2 mRNA expression was (Figure 2, B) . After treatment with methylprednisolone, donor PCLS grouped according to the SP-A1/SP-A2 genotype (Table 2) showed (Figure 3, A) that SP-A1 mRNA expression was as follows: for group 6A 2 6A 2 /1A 0 1A 0 median 3.9 (2.4-4.1) and for group ''other'' 0.8 (0.6-3.1.8) (P ¼ .004). The SP-A2 mRNA expression was for 6A 2 6A 2 /1A 0 1A 0 median 2.1 (1.9-2.7) and for group ''other'' 0.9 (0.6-1.7) (P ¼ .047). Similar to findings for SP-A2 variants, after methylprednisolone treatment, PCLS from donor lung with SP-A1/SP-A2 genotypes showed that SP-A protein expression was higher compared with the ''other'' group (Figure 3, B) . In particular, SP-A protein expression was for genotype 6A 2 6A 2 /1A 0 1A 0 median 1.5 (1.2-8.7), and for the ''other'' genotypes was median 0.3 (0.2-1.5) (Mann-Whitney test P ¼ .042).
Surfactant Protein D Variants and Methylprednisolone Responses in Human Precision-Cut Lung Slices
The polymorphisms for aa11 (Met 11 Thr) and aa160 (Ala 160 Thr) of the donor lungs are shown in Table 4 . After methylprednisolone treatment, SP-D mRNA expression in the PCLS cultures showed no significant association with the aa11 and the aa160 variants (Figure 4 We initially tested human lung adenocarcinoma NCI-H441 cells. These cells were chosen because they are the only cells that express SP-A in a consistent manner. [28] [29] [30] [31] Of note, the NCI-H441 human cell line expresses an uncommon SP-A1/SP-A2 genotype (6A 4 6A 4 /1A 5 1A 5 ). 32 NCI-H441 cells were treated with methylprednisolone at a 10-fold incremental dose from 10 À9 M to 10 À5 M. Methylprednisolone at high concentrations significantly reduced the mRNA and protein expression of SP-A compared with lower doses. These observations confirm what was previously reported using dexamethasone in the same cell line. 28, 29 Methylprednisolone and dexamethasone, although both are glucocorticoids, have different clinical applications and dexamethasone rarely is used in clinical lung transplantation because it is associated with worse clinical outcomes. A similar investigation was then conducted in a human donor PCLS culture model. This is a more difficult model to implement, particularly from a logistic standpoint given that human donor lungs available for research are a scarce resource, although it is the most relevant biological model from which meaningful clinical conclusions can be drawn. The SP-A1 and SP-A2 variant frequencies seen in our donor lung study population (Table 1) reflect that of the larger patient populations described in the literature. 10, 13, 27 Within the cohort of 16 donor lungs tested, 5 lung grafts (Table 1) had the SP-A1/SP-A2 genotype 6A 2 6A 2 /1A 0 1A 0 , which is the most common genotype identified in the human population. 10, 13, 27 When investigating PCLS in human donors and the pharmacogenetic relationship between methylprednisolone treatment and the SP-A1 and SP-A2 most frequent variants, our results indicated that the SP-A1 variants 6A 2 and 6A Values are the number of patients with the specified SP-D variant. SP, Surfactant protein.
( Table 2 ) consistently showed a significantly greater SP-A1 and SP-A2 mRNA (Figure 3, A) and SP-A protein expression after methylprednisolone treatment (Figure 3, B) . Moreover, SP-D expression was also subject to the SP-A pharmacogenetic interaction with methylprednisolone ( Figure 4 ). In contrast, no pharmacogenetic relationship was noted with the 2 most frequent SP-D single nucleotide polymorphisms (aa11 and aa160) that were investigated. It is not understood how the pharmacogenetic relationship between methylprednisolone and SP-A2 variants is associated with SP-A 1 and SP-D expression. SP-A2 was recently shown to regulate microRNA, which we speculate could in turn regulate the SP-A and SP-D expression. 33 The results derived from the human donor PCLS model were different from the findings using the human lung cancer cell model with an SP-A1/SP-A2 genotype 6A 4 6A 4 /1A 5 1A 5 . The cell line showed a significant reduction of SP-A expression when methylprednisolone was used at high doses (Figure 1 ), but this was not observed at low doses. The human cancer cells we have used in this study express a rare SP-A genotype. Although the results are from different models (immortalized adenocarcinoma cells and PCLS cultures), it is possible that some of the less frequent or rare genotypes encountered in the human population may eventually show a similar response as observed in NCI-H441 cells.
Glucocorticoids have been shown to have a biphasic regulation of the SP-A expression either stimulating or inhibiting accumulation in cultured human fetal lungs depending on the dose and time of exposure. 30, 31 Moreover, there appears to be a differential regulation of the SP-A1 and SP-A2 genes. 24, 25, 31, 32 Glucocorticoid treatment in vivo using a preterm sheep model triggered SP-A expression. 34 The concentrations of methylprednisolone used in our experiments mimic those reported in the literature investigating in vitro the hormonal regulation of SP-A expression. [28] [29] [30] [31] [32] 34 How they relate to the doses used in the clinical transplant setting is difficult to extrapolate. It is not possible to exactly compare the doses used regularly in clinical treatment administered intravenously according to patient weight with the concentration of the drug administered in the culture media in our cell and PCLS cultures, and not knowing the weight of the cells and tissues.
Our results in the human PCLS model showed no influence of the methylprednisolone dose but did show a definite diverse pattern of SP-A expression according to the SP-A polymorphic variants. Our results suggest that lung allografts according to their SP-A genotypes may be able to provide potentially greater or less active surfactant innate immune system after lung transplantation, given the same regimen of steroid treatment. In particular, lungs with SP-A genotype 6A 2 6A 2 /1A 0 1A 0 showed a significantly greater SP-A expression after methylprednisolone treatment ( Figure 3, A and B) .
The information generated from our study is of interest given that the lung-specific innate immunity provided by surfactant and its proteins plays an important role in the first line of defense from the various noxious events encountered in lung transplantation.
1-3 SP-A was reduced in a rodent model of lung transplant ischemia-reperfusion injury, and endobronchial treatment with SP-A-enriched surfactant improved lung function. 35 Moreover, in humanized transgenic mice in which each was carrying a different SP-A variant, differences in lung function were observed after infection. 36 We reported that the donor lung allograft SP-A and SP-D polymorphism influence the posttransplant outcomes. [24] [25] [26] In particular, SP-A2 variant 1A 0 has a protective effect toward survival. In humanized transgenic mice, those carrying SP-A2 variant 1A0 had greater survival after Klebsiella pneumonia infection. 37 Lung transplant recipients of allografts with SP-A2 genotype 1A 0 -1A 0 had significantly greater SP-A mRNA expression before implantation, which resulted in improved clinical outcomes. 24, 25 Of note, donors before organ procurement are treated with 1 to 2 g of intravenous methylprednisolone every 12 hours, and lung transplant recipients are treated with 0.5 mg/kg of methylprednisolone early post-transplant, which is slowly tapered over the first year, thereafter reaching a maintenance dose of 5 to 10 mg twice per day. Reduced levels of SP-A and SP-D proteins in the bronchoalveolar lavage collected at surveillance bronchoscopies in lung transplant recipients are associated with the development of lung allograft dysfunction. 38 
CONCLUSIONS
Our findings, although acquired from a small cohort of human donor lungs, show for the first time and serve as proof-of-concept that there is a significant pharmacogenetic relationship between the SP-A polymorphic genotype and the methylprednisolone treatment on SP-A expression. Of note, these findings are donor lung related and not recipient driven. Further studies are required on donor lungs for the purpose of identifying different genotypes that are associated with different patterns of expression from that observed in the current cohort of human donor lungs or the human cancer cell line genotype as a response of these genotypes to methylprednisolone treatment. These findings will need to be confirmed in vivo. The findings from this and future pharmacogenetic studies in lung transplantation may stimulate further research investigating immunosuppressive regimens tailored according to the genetic background of the donor lung. These putative future regimens could then be implemented in the routine management of lung transplant recipients.
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